Conclusions and implication s of key findings : Fluoxetine is associated with a significantly greater reduction in OCD severity , as measured by the CY-BOCS , NIMH-OC and CGI-S , in children and adolescents .
Additionally , it is well tolerated in children and adolescents .
The acceptability is comparable to that of the placebo-treated group .
Background : Obsessive-compulsive disorder ( OCD ) is a common psychiatric illness in children and adolescents .
Previous evidence suggests that fluoxetine is effective in the treatment of OCD in children and adolescents .
However , those studies had small sample sizes .
As a result , a systematic review , which is a more powerful method to calculate the true effect size , can be applied to examine the efficacy , acceptability and tolerability of fluoxetine in the treatment of OCD in children and adolescents .
Objectives : The aims of this study were to review the efficacy , acceptability and tolerability of fluoxetine in the treatment of OCD in children and adolescents .
Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
OBJECTIVE To determine the safety and efficacy of fluvoxamine for the treatment of children and adolescents with obsessive-compulsive disorder ( OCD ) with a double-blind , placebo-controlled , multicenter study . METHOD Subjects , aged 8 to 17 years , meeting DSM-III-R criteria for OCD were recruited from July 1991 to August 1994 . After a 7- to 14-day single-blind , placebo washout/screening period , subjects were r and omly assigned to fluvoxamine 50 to 200 mg/day or placebo for 10 weeks . Subjects who had not responded after 6 weeks could discontinue the double-blind phase of the study and enter a long-term , open-label trial of fluvoxamine . Analyses used an intent-to-treat sample with a last-observation-carried-forward method . RESULTS Mean Children 's Yale-Brown Obsessive Compulsive Scale ( CY-BOCS ) scores with fluvoxamine were significantly ( p < .05 ) different from those with placebo at weeks 1 , 2 , 3 , 4 , 6 , and 10 . Significant ( p < .05 ) differences between fluvoxamine and placebo were observed for all secondary outcome measures at all visits . Based on a 25 % reduction of CY-BOCS scores , 42 % of subjects taking fluvoxamine were responders compared with 26 % taking placebo . Forty-six ( 19 fluvoxamine , 27 placebo ) of 120 r and omized subjects discontinued early . Adverse events with a placebo-adjusted rate greater than 10 % were insomnia and asthenia . CONCLUSIONS Fluvoxamine has a rapid onset of action and is well tolerated and efficacious for the short-term treatment of pediatric OCD
Conclusions and implication s of key findings : Fluoxetine is associated with a significantly greater reduction in OCD severity , as measured by the CY-BOCS , NIMH-OC and CGI-S , in children and adolescents .
Additionally , it is well tolerated in children and adolescents .
The acceptability is comparable to that of the placebo-treated group .
Background : Obsessive-compulsive disorder ( OCD ) is a common psychiatric illness in children and adolescents .
Previous evidence suggests that fluoxetine is effective in the treatment of OCD in children and adolescents .
However , those studies had small sample sizes .
As a result , a systematic review , which is a more powerful method to calculate the true effect size , can be applied to examine the efficacy , acceptability and tolerability of fluoxetine in the treatment of OCD in children and adolescents .
Objectives : The aims of this study were to review the efficacy , acceptability and tolerability of fluoxetine in the treatment of OCD in children and adolescents .